Christopher Ray Aker Sells 38,547 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,569.22. Following the completion of the transaction, the vice president now directly owns 54,634 shares of the company’s stock, valued at $68,838.84. The trade was a 41.37 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Regulus Therapeutics Stock Up 0.8 %

Regulus Therapeutics stock opened at $1.28 on Friday. The stock has a 50-day moving average price of $1.52 and a 200 day moving average price of $1.58. The company has a market capitalization of $83.84 million, a price-to-earnings ratio of -1.20 and a beta of 1.60. Regulus Therapeutics Inc. has a 52 week low of $1.08 and a 52 week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

Several hedge funds have recently added to or reduced their stakes in RGLS. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics during the 3rd quarter valued at about $10,154,000. Point72 Asset Management L.P. acquired a new stake in Regulus Therapeutics during the third quarter worth about $1,403,000. Bank of New York Mellon Corp purchased a new position in Regulus Therapeutics during the second quarter valued at approximately $352,000. The Manufacturers Life Insurance Company purchased a new position in Regulus Therapeutics during the third quarter valued at approximately $204,000. Finally, Tyche Wealth Partners LLC lifted its holdings in Regulus Therapeutics by 920.6% in the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 95,694 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.